Mizuho Markets Americas LLC Makes New $11.67 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Mizuho Markets Americas LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 195,613 shares of the specialty pharmaceutical company's stock, valued at approximately $11,670,000. Mizuho Markets Americas LLC owned approximately 0.93% of ANI Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ANIP. Innealta Capital LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $85,000. SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $106,000. O Shaughnessy Asset Management LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $218,000. Finally, XTX Topco Ltd bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $207,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Raymond James increased their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $77.33.

ANI Pharmaceuticals Stock Down 4.0 %

NASDAQ:ANIP traded down $2.33 during midday trading on Friday, reaching $56.58. 293,055 shares of the stock traded hands, compared to its average volume of 218,111. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The business has a 50-day moving average of $58.40 and a two-hundred day moving average of $61.34. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a market capitalization of $1.19 billion, a PE ratio of -102.87 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.05 earnings per share. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.